Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Abstract
Rituximab is effective at inducing and maintaining remission in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The wide interpatient variability in the duration of B-cell depletion and time to relapse as well as the significant relapse risk after treatment, costs, and adverse event rates necessitate improved patient stratification.
Description
Keywords
Adult, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Antirheumatic Agents, B-Cell Activating Factor, B-Lymphocytes, Biomarkers, Pharmacological, Cohort Studies, Female, Humans, Lymphocyte Depletion, Male, Middle Aged, Polymorphism, Single Nucleotide, Regulatory Sequences, Nucleic Acid, Rituximab
Journal Title
Journal of Allergy and Clinical Immunology
Conference Name
Journal ISSN
0091-6749
1097-6825
1097-6825
Volume Title
139
Publisher
Elsevier
Publisher DOI
Rights and licensing
Except where otherwised noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
Sponsorship
Medical Research Council (MR/L019027/1)
This study was supported by the National Institute of Health Research Cambridge Biomedical Research Centre (http://www.cambridge-brc.org.uk). F.A. has been supported by a European Renal Association-European Dialysis and Transplant Association long-term fellowship between September 2012 and September 2013. A.V. and D.M. were supported by the grant “A tailored approach to the immune monitoring and clinical management of viral and autoimmune diseases,” given by the Regione Emilia-Romagna within the Programma di Ricerca Regione-Università 2010–12.